One Wealth Capital Management LLC Takes Position in Novo Nordisk A/S (NYSE:NVO)

One Wealth Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,090 shares of the company’s stock, valued at approximately $438,000.

Several other hedge funds have also added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in Novo Nordisk A/S by 0.4% in the second quarter. Rhumbline Advisers now owns 60,974 shares of the company’s stock valued at $8,703,000 after purchasing an additional 270 shares during the last quarter. Savant Capital LLC grew its holdings in Novo Nordisk A/S by 16.2% during the second quarter. Savant Capital LLC now owns 12,587 shares of the company’s stock valued at $1,797,000 after purchasing an additional 1,751 shares during the period. Strategic Financial Concepts LLC increased its stake in Novo Nordisk A/S by 12,106.7% in the second quarter. Strategic Financial Concepts LLC now owns 206,172 shares of the company’s stock valued at $294,000 after purchasing an additional 204,483 shares in the last quarter. Chris Bulman Inc acquired a new stake in Novo Nordisk A/S in the second quarter worth $71,000. Finally, Certuity LLC boosted its position in shares of Novo Nordisk A/S by 83.6% during the second quarter. Certuity LLC now owns 4,416 shares of the company’s stock worth $630,000 after purchasing an additional 2,011 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. Finally, BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Down 2.4 %

NYSE:NVO traded down $2.01 during trading hours on Tuesday, reaching $83.02. 7,498,431 shares of the stock were exchanged, compared to its average volume of 6,482,653. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The stock has a market cap of $372.55 billion, a PE ratio of 26.87, a PEG ratio of 1.37 and a beta of 0.45. The firm has a 50 day moving average of $102.51 and a 200 day moving average of $120.68.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.